INSTITUTE FOR VIRAL AND LIVER DISEASES

WELCOME TO OUR INSTITUTE

At Inserm U1110 our objective is to push knowledge to new limits in our quest for novel therapeutics for liver disease. Through the creation of clusters of excellence and cutting edge translational research:

We translate discoveries into clinical applications
We train first class researchers of the future

Play Video

OUR MISSIONS

Advanced Liver Diseases:
the new silent killer

Advanced Liver Diseases: the new silent killer

ADVANCED LIVER DISEASES

Fatty liver disease, NASH, Fibrosis

Complications

Complications:

LIVER CANCER

LIVER CANCER

NO EARLY DIAGNOSIS - NO EXISTING TREATMENTS

OUR INNOVATION PROGRAM

Picture4

Develop
Liquid
Biopsy

path30683

Treat
Early
Stages

g69384

Treat
Advanced
Stages

JOIN OUR CAUSE!

200,000 euros

already collected
thanks to your donations.

We still need your help!

Inserm U1110
Institute for Viral and Liver Diseases

3, Rue Koeberlé
67000 Strasbourg
FRANCE

Inserm U1110 strasbourg baumert

IN SHORT

The strength of our institute is the full integration of basic, translational, and clinical research, along with the establishment of strong collaborations and networks of excellence with leading experts from the field at local and international level. We made major contributions to the field, supported by a long-standing track record, in the understanding of viral and metabolic pathogenesis of liver disease and their translation into clinical applications, including the development of novel preventive and therapeutic strategies. Our key aims are: unravel the cell circuits driving liver disease progression, develop innovative patient-derived models for liver disease,  characterize SARS-CoV-2 / HBV / HCV /HDV – hepatocytes interactions,  translate discoveries into novel therapeutic strategies.

By providing a novel understanding of liver disease biology and by discovering novel targets and biomarkers, our programs aim to impact the management of patients with liver disease and liver cancer in France, Europe, and beyond.